66 related articles for article (PubMed ID: 24438083)
1. Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia.
Varghese LN; Zhang JG; Young SN; Willson TA; Alexander WS; Nicola NA; Babon JJ; Murphy JM
Growth Factors; 2014 Feb; 32(1):18-26. PubMed ID: 24438083
[TBL] [Abstract][Full Text] [Related]
2. Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).
Chen WM; Yu B; Zhang Q; Xu P
J Biol Chem; 2010 Aug; 285(34):26697-709. PubMed ID: 20529857
[TBL] [Abstract][Full Text] [Related]
3. Congenital amegakaryocytic thrombocytopenia: a brief review of the literature.
Al-Qahtani FS
Clin Med Insights Pathol; 2010 Jun; 3():25-30. PubMed ID: 21151552
[TBL] [Abstract][Full Text] [Related]
4. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.
Tsutsumi N; Masoumi Z; James SC; Tucker JA; Winkelmann H; Grey W; Picton LK; Moss L; Wilson SC; Caveney NA; Jude KM; Gati C; Piehler J; Hitchcock IS; Garcia KC
Cell; 2023 Sep; 186(19):4189-4203.e22. PubMed ID: 37633268
[TBL] [Abstract][Full Text] [Related]
5. Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease.
Behrens K; Kauppi M; Viney EM; Kueh AJ; Hyland CD; Willson TA; Salleh L; de Graaf CA; Babon JJ; Herold MJ; Nicola NA; Alexander WS
Leukemia; 2024 Jun; 38(6):1342-1352. PubMed ID: 38491305
[TBL] [Abstract][Full Text] [Related]
6. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Erickson-Miller CL; Pillarisetti K; Kirchner J; Figueroa DJ; Ottesen L; Martin AM; Liu Y; Kamel YM; Messam C
BMC Cancer; 2012 Sep; 12():405. PubMed ID: 22967017
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure.
Ammeti D; Marzollo A; Gabelli M; Zanchetta ME; Tretti-Parenzan C; Bottega R; Capaci V; Biffi A; Savoia A; Bresolin S; Faleschini M
Br J Haematol; 2023 Dec; 203(5):852-859. PubMed ID: 37610030
[TBL] [Abstract][Full Text] [Related]
8. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin.
Frederickson S; Renshaw MW; Lin B; Smith LM; Calveley P; Springhorn JP; Johnson K; Wang Y; Su X; Shen Y; Bowdish KS
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14307-12. PubMed ID: 16973749
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling.
Sangkhae V; Saur SJ; Kaushansky A; Kaushansky K; Hitchcock IS
Exp Hematol; 2014 Jun; 42(6):477-86.e4. PubMed ID: 24607955
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin from beginning to end.
Hitchcock IS; Kaushansky K
Br J Haematol; 2014 Apr; 165(2):259-68. PubMed ID: 24499199
[TBL] [Abstract][Full Text] [Related]
11. Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin.
Sarson-Lawrence KTG; Hardy JM; Iaria J; Stockwell D; Behrens K; Saiyed T; Tan C; Jebeli L; Scott NE; Dite TA; Nicola NA; Leis AP; Babon JJ; Kershaw NJ
Nat Commun; 2024 Feb; 15(1):1135. PubMed ID: 38326297
[TBL] [Abstract][Full Text] [Related]
12. The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants.
Stefanucci L; Collins J; Sims MC; Barrio-Hernandez I; Sun L; Burren OS; Perfetto L; Bender I; Callahan TJ; Fleming K; Guerrero JA; Hermjakob H; Martin MJ; Stephenson J; Paneerselvam K; Petrovski S; Porras P; Robinson PN; Wang Q; Watkins X; Frontini M; Laskowski RA; Beltrao P; Di Angelantonio E; Gomez K; Laffan M; Ouwehand WH; Mumford AD; Freson K; Carss K; Downes K; Gleadall N; Megy K; Bruford E; Vuckovic D
Blood; 2023 Dec; 142(24):2055-2068. PubMed ID: 37647632
[TBL] [Abstract][Full Text] [Related]
13. Structural modeling of cytokine-receptor-JAK2 signaling complexes using AlphaFold Multimer.
Pogozheva ID; Cherepanov S; Park SJ; Raghavan M; Im W; Lomize AL
bioRxiv; 2023 Jun; ():. PubMed ID: 37398331
[TBL] [Abstract][Full Text] [Related]
14. Effects of calreticulin mutations on cell transformation and immunity.
Desikan H; Kaur A; Pogozheva ID; Raghavan M
J Cell Mol Med; 2023 Apr; 27(8):1032-1044. PubMed ID: 36916035
[TBL] [Abstract][Full Text] [Related]
15. In and out: Traffic and dynamics of thrombopoietin receptor.
Roy A; Shrivastva S; Naseer S
J Cell Mol Med; 2021 Oct; 25(19):9073-9083. PubMed ID: 34448528
[TBL] [Abstract][Full Text] [Related]
16. CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients.
Germeshausen M; Ballmaier M
Haematologica; 2021 Sep; 106(9):2439-2448. PubMed ID: 32703794
[TBL] [Abstract][Full Text] [Related]
17. Gene editing rescue of a novel
Cleyrat C; Girard R; Choi EH; Jeziorski É; Lavabre-Bertrand T; Hermouet S; Carillo S; Wilson BS
Blood Adv; 2017 Sep; 1(21):1815-1826. PubMed ID: 29296828
[TBL] [Abstract][Full Text] [Related]
18. Identification of
Bellanné-Chantelot C; Mosca M; Marty C; Favier R; Vainchenker W; Plo I
Front Endocrinol (Lausanne); 2017; 8():235. PubMed ID: 28979237
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
